KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31

Karyopharm Therapeutics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.35−0.04 (-11.30%)

Close on Oct 19, 2026

Market cap: $10.01K
P/E (TTM): –
Dividend yield: –

Karyopharm Therapeutics Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31	TTM Q3 2020 2020-09-30	TTM Q2 2020 2020-06-30	TTM Q1 2020 2020-03-31	TTM FY 2019 2019-12-31	TTM Q3 2019 2019-09-30	TTM Q2 2019 2019-06-30	TTM Q1 2019 2019-03-31	TTM FY 2018 2018-12-31	TTM Q3 2018 2018-09-30	TTM Q2 2018 2018-06-30	TTM Q1 2018 2018-03-31	TTM FY 2017 2017-12-31	TTM Q3 2017 2017-09-30	TTM Q2 2017 2017-06-30	TTM Q1 2017 2017-03-31	TTM FY 2016 2016-12-31	TTM Q3 2016 2016-09-30
Revenue	147	151	146	143	137	142	145	148	146	140	146	146	146	148	157	250	251	234	210	119	102	113	108	91	83	59	41	23	10	20	30	32	31	12	1.61	0.12	0.17	0.22	0.15	–
Research & Development	121	125	126	131	137	142	143	149	149	142	139	130	126	139	149	162	176	166	161	154	145	154	151	145	134	118	122	130	140	158	161	157	146	125	107	93	88	89	87	90
Selling, General & Admin	102	105	105	110	111	113	115	119	122	126	132	136	140	143	145	145	146	145	144	143	139	133	126	121	115	109	105	96	84	–	49	–	–	–	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	84	68	49	36	29	26	25	25	25	25	24	23
Operating Expenses	229	235	237	247	252	261	265	274	277	273	276	271	271	287	299	311	326	315	308	301	288	290	280	269	253	231	230	226	223	226	210	194	175	151	132	118	113	114	111	113
Operating Income	-82	-84	-91	-104	-115	-119	-119	-126	-131	-132	-130	-126	-125	-139	-142	-61	-74	-80	-98	-182	-186	-177	-172	-178	-170	-172	-189	-203	-213	-206	-180	-162	-144	-139	-131	-118	-113	-114	-111	-113
Interest Expense	49	47	46	44	45	43	37	32	27	24	24	24	24	24	25	27	29	28	26	25	24	26	27	27	23	19	16	–	–	–	–	–	–	–	–	–	–	–	–	–
Interest & Investment Income	2.39	2.28	2.77	3.65	4.93	6.24	7.40	8.44	9.36	10	11	9.76	7.67	5.13	2.36	1.08	0.52	0.39	0.58	0.92	1.43	2.11	2.82	3.53	4.06	4.63	5.42	6.09	6.05	5.29	4.03	2.69	2.05	1.81	1.70	1.62	1.48	1.40	1.28	1.18
Other Non-Operating Income	-142	-111	-105	-20	-8.36	56	43	39	41	-14	-13	-14	-16	-19	-23	-27	-29	-27	-26	-23	-22	-23	-24	-23	-19	-15	-10	-5.65	-2.62	-0.24	1.50	2.66	2.00	1.73	1.62	1.57	1.45	1.39	1.29	1.18
Pretax Income	-225	-195	-196	-125	-124	-63	-76	-87	-90	-146	-143	-140	-141	-158	-165	-88	-103	-108	-124	-206	-208	-200	-196	-201	-189	-186	-200	-209	-216	-206	-178	-159	-142	-137	-129	-117	-111	-112	-109	–
Income Tax Expense	-0.03	0.01	0.04	0.00	-0.01	0.02	0.06	0.30	0.28	0.34	0.32	0.27	0.30	0.29	0.37	0.18	0.24	0.25	0.27	0.45	0.39	0.39	0.31	0.25	0.23	0.10	0.04	0.06	0.05	0.02	0.03	0.02	0.02	0.05	0.06	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-225	-195	-196	-125	-124	-63	-76	-87	-90	-146	-143	-140	-142	-158	-165	-88	-104	-108	-124	-206	-208	-201	-196	-201	-189	-186	-200	-209	-216	-206	-178	-159	-142	–	-129	–	–	–	–	–
Net Income	-225	-195	-196	-125	-124	-63	-76	-87	-90	-146	-143	-140	-142	-158	-165	-88	-104	-108	-124	-206	-208	-201	-196	-201	-189	-186	-200	-209	-216	-206	-178	-159	-142	-138	-129	-117	-112	-112	-110	-112
Net Income to Common	–	–	–	–	–	–	-118	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-16.33	-19.93	-21.28	-24.75	-41.38	-41.98	-40.78	-40.80	-43.51	-42.61	-43.81	-48.30	-51.45	-53.25	-51.60	-47.10	-44.55	-42.45	-43.05	-42.15	-39.75	-40.35	-43.35	-43.80	-46.35
EPS (Diluted)(per share)	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-16.33	-19.93	-21.28	-24.75	-41.38	-41.98	-40.78	-40.80	-43.51	-42.61	-43.81	-48.30	-51.45	-53.25	-51.60	-47.10	-44.55	-42.45	-43.05	-42.15	-39.75	-40.35	-43.35	-43.80	-46.35
Shares Outstanding (Basic, Weighted)(shares)	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	1.91	0.01	–	–	–	–	5.22	5.14	5.06	5.01	4.98	4.95	4.92	4.80	3.51	2.29	1.07	4.13	–	–	–	–	3.58	3.36	3.19	3.06	2.94	2.77	2.60	2.50	2.41
Shares Outstanding (Diluted, Weighted)(shares)	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	1.91	0.01	–	–	–	–	5.22	5.14	5.06	5.01	4.98	4.95	4.92	4.80	3.51	2.29	1.07	4.13	–	–	–	–	3.58	3.36	3.19	3.06	2.94	2.77	2.60	2.50	2.41
EBITDA	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-177	-169	-171	-188	-203	-212	-205	-179	-161	-143	-139	-130	-118	-112	-113	-110	-112

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -56.2%
Net margin: -153.3%
Return on equity, FY2025: 81.9%

Financial strength

Current ratio: 0.79
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 41.0%

Valuation

P/E ratio: –
Price to sales: 0.00
Price to book: –
Dividend yield: –